Aripiprazole Tablet
Product Images NDC 70518-2974

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2974). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Aripiprazole 30mg 70518 2974 01)

Packaging label for Aripiprazole 30 mg oral tablets, quantity of 30, labeled for prescription use only (RX ONLY). The label shows the NDC number 70518-2974-01 and indicates repackaging by RemedyRepack Inc. The manufacturer is Ascend Labs, LLC, Montvale, NJ. Storage instructions and a QR code are also visible.*

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A line chart comparing the proportion of relapse over time between Aripiprazole and placebo groups. The x-axis represents days from randomization (0 to 182 days), and the y-axis shows the proportion of subjects with relapse (0 to 1.0). The chart includes a subject risk table below the x-axis for both groups at various time points.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over days from randomization, comparing Aripiprazole and placebo groups. The X-axis represents days from randomization (0 to 364 days), and the Y-axis represents the proportion with relapse (0 to 1.0). The chart includes a risk table showing the number of subjects at risk at various time points for both groups.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the effects of various interacting drugs, including CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and others, on the change in AUC and Cmax of Dehydro-Aripiprazole relative to a reference without interacting drugs.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A forest plot showing fold changes and 90% confidence intervals in pharmacokinetic parameters (AUC and Cmax) and INR for various drugs when taken with or without an interacting drug. The plot includes drugs like dextromethorphan, warfarin, omeprazole, valproate, lithium, venlafaxine, escitalopram, and others, with their relative changes compared to a reference.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart depicting fold change and 90% confidence intervals of Aripiprazole plasma exposure variables (AUC and Cmax) across various factors. Factors include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The chart shows the relative change compared to reference conditions for each factor.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the effects of various factors (CYP2D6 metabolism status, gender, age, hepatic impairment, and severe renal impairment) on AUC and Cmax relative to reference values. The x-axis represents change relative to reference, ranging from 0.5 to 3.0, with data points and confidence intervals displayed for each factor comparison.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic (PK) chart illustrating the fold change and 90% confidence intervals (CI) of aripiprazole exposure, measured by AUC and Cmax, when co-administered with various inhibitors, inducers, and other drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam. The x-axis shows change relative to reference without interacting drug.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Aripiprazole 30 mg tablet, quantity 30, repackaged by RemedyRepack Inc. The label includes dosage strength, dosage form, NDC number 70518-2974-00, manufacturer info for Ascend Labs LLC in Montvale, NJ, and storage instructions. The label also features a QR code and a warning to keep medication out of reach of children.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure diagram of the active ingredient Aripiprazole, as shown in the image. The structure includes characteristic aromatic rings, a piperazine ring, and chlorophenyl groups consistent with Aripiprazole's molecular composition.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A line graph depicting the proportion of subjects with relapse over days from randomization comparing Aripiprazole and placebo groups. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse ranging from 0 to 1. The graph includes subject risk numbers at various time points for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.